AssureMDx is a noninvasive urine-based test that assesses key biomarkers – DNA methylation status and somatic mutations – to identify patients at increased risk for bladder cancer. It helps physicians accurately triage hematuria patients, enabling timely referral to urology and potentially avoiding unnecessary invasive procedures. This innovative test improves early detection and contributes to better patient outcomes.